FindTrial
Sign In

A study on the impact of pan-immune inflammation values on the clinical prognosis of heart failure patients with different ejection fractions

A study on the impact of pan-immune inflammation values on the clinical prognosis of heart failure patients with different ejection fractions

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119023
Enrollment
Unknown
Registered
2026-02-14
Start date
2025-07-25
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

HFpEF group:none.
HFrEF+HFmrEF group:none

Sponsors

The First Central Hospital of Tianjin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who were hospitalized at Tianjin First Central Hospital from September 2019 to December 2022 are proposed to be included. The inclusion criteria are as follows: 1. NYHA grade 3-4 for heart failure; 2. Age >=18 years old; 3. There are baseline pan-immune inflammation value data .

Exclusion criteria

Exclusion criteria: The required indicators for research such as left ventricular ejection fraction by echocardiography, blood routine, and biochemistry are lacking. Combined with malignant tumors; Combined with severe hematological diseases; Combined with severe renal or liver dysfunction.

Design outcomes

Primary

MeasureTime frame
Death event;Area under the ROC curve;—

Countries

China

Contacts

Public ContactChengzhi Lu

The First Central Hospital of Tianjin

5020200072@nankai.edu.cn+86 135 1296 7656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026